Emerging research suggest Retatrutide , a dual agonist targeting both the gut-brain axis and another hormone, could represent a notable advancement for obesity loss . Early human investigations have indicated impressive losses in abdominal tissue, potentially exceeding current obesity medications . Nevertheless , more evaluation is necessary to com